| Mr Shannon Paul Weisz, PSYD, LAC | |
|
309 N Mandan St, Suite #1, Bismarck, ND 58501-3886 | |
| (701) 323-0924 | |
| (701) 323-0935 |
| Full Name | Mr Shannon Paul Weisz |
|---|---|
| Gender | Male |
| Speciality | Clinical Psychologist |
| Experience | 13 Years |
| Location | 309 N Mandan St, Bismarck, North Dakota |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1730254418 | NPI | - | NPPES |
| 17326 | Medicaid | ND |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 103T00000X | Psychologist | 470 (North Dakota) | Primary |
| 101YA0400X | Counselor - Addiction (substance Use Disorder) | 1549 (North Dakota) | Secondary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Missouri River Health | 0648684324 | 4 |
News Archive
A team of Massachusetts General Hospital researchers has developed a potential alternative to gadolinium-based contrast agents (GBCAs) for magnetic resonance imaging.
The Agency for Healthcare Research and Quality (AHRQ) and the Patient-Centered Outcomes Research Institute (PCORI) today announced $40 million in awards over five years to 11 institutions to support the training of researchers to conduct patient-centered outcomes research (PCOR) within learning health systems (LHS).
Affomix Corporation, a pioneer in the development of automated, high-throughput monoclonal antibody selection technology, announced today that Kalgene Pharmaceuticals Inc. has signed a commercial agreement to have Affomix utilize its Y2HExpress™ technology to select antibodies with potential diagnostic and therapeutic utility in breast cancer. Kalgene Pharmaceuticals Inc. is a private company focused on the development of oncology therapeutics and companion diagnostics.
An unfortunate side effect of the platinum-chemotherapy drug oxaliplatin is the development of neurotoxicity, which can adversely affect a patient's quality of life; therefore, the benefit of oxaliplatin-based therapy must be balanced with prevention of neuropathies. Currently, there are no therapeutic interventions available to relieve oxaliplatin-associated neurological symptoms, which are thought to be a result of reactive oxygen species-associated damage.
› Verified 6 days ago
| Entity Name | Chambers & Blohm Psychological |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1114045465 PECOS PAC ID: 1456248004 Enrollment ID: O20040301000177 |
News Archive
A team of Massachusetts General Hospital researchers has developed a potential alternative to gadolinium-based contrast agents (GBCAs) for magnetic resonance imaging.
The Agency for Healthcare Research and Quality (AHRQ) and the Patient-Centered Outcomes Research Institute (PCORI) today announced $40 million in awards over five years to 11 institutions to support the training of researchers to conduct patient-centered outcomes research (PCOR) within learning health systems (LHS).
Affomix Corporation, a pioneer in the development of automated, high-throughput monoclonal antibody selection technology, announced today that Kalgene Pharmaceuticals Inc. has signed a commercial agreement to have Affomix utilize its Y2HExpress™ technology to select antibodies with potential diagnostic and therapeutic utility in breast cancer. Kalgene Pharmaceuticals Inc. is a private company focused on the development of oncology therapeutics and companion diagnostics.
An unfortunate side effect of the platinum-chemotherapy drug oxaliplatin is the development of neurotoxicity, which can adversely affect a patient's quality of life; therefore, the benefit of oxaliplatin-based therapy must be balanced with prevention of neuropathies. Currently, there are no therapeutic interventions available to relieve oxaliplatin-associated neurological symptoms, which are thought to be a result of reactive oxygen species-associated damage.
› Verified 6 days ago
| Entity Name | Missouri River Health |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1013513134 PECOS PAC ID: 0648684324 Enrollment ID: O20210121001544 |
News Archive
A team of Massachusetts General Hospital researchers has developed a potential alternative to gadolinium-based contrast agents (GBCAs) for magnetic resonance imaging.
The Agency for Healthcare Research and Quality (AHRQ) and the Patient-Centered Outcomes Research Institute (PCORI) today announced $40 million in awards over five years to 11 institutions to support the training of researchers to conduct patient-centered outcomes research (PCOR) within learning health systems (LHS).
Affomix Corporation, a pioneer in the development of automated, high-throughput monoclonal antibody selection technology, announced today that Kalgene Pharmaceuticals Inc. has signed a commercial agreement to have Affomix utilize its Y2HExpress™ technology to select antibodies with potential diagnostic and therapeutic utility in breast cancer. Kalgene Pharmaceuticals Inc. is a private company focused on the development of oncology therapeutics and companion diagnostics.
An unfortunate side effect of the platinum-chemotherapy drug oxaliplatin is the development of neurotoxicity, which can adversely affect a patient's quality of life; therefore, the benefit of oxaliplatin-based therapy must be balanced with prevention of neuropathies. Currently, there are no therapeutic interventions available to relieve oxaliplatin-associated neurological symptoms, which are thought to be a result of reactive oxygen species-associated damage.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mr Shannon Paul Weisz, PSYD, LAC 309 N Mandan St, Suite #1, Bismarck, ND 58501-3886 Ph: (701) 323-0924 | Mr Shannon Paul Weisz, PSYD, LAC 309 N Mandan St, Suite #1, Bismarck, ND 58501-3886 Ph: (701) 323-0924 |
News Archive
A team of Massachusetts General Hospital researchers has developed a potential alternative to gadolinium-based contrast agents (GBCAs) for magnetic resonance imaging.
The Agency for Healthcare Research and Quality (AHRQ) and the Patient-Centered Outcomes Research Institute (PCORI) today announced $40 million in awards over five years to 11 institutions to support the training of researchers to conduct patient-centered outcomes research (PCOR) within learning health systems (LHS).
Affomix Corporation, a pioneer in the development of automated, high-throughput monoclonal antibody selection technology, announced today that Kalgene Pharmaceuticals Inc. has signed a commercial agreement to have Affomix utilize its Y2HExpress™ technology to select antibodies with potential diagnostic and therapeutic utility in breast cancer. Kalgene Pharmaceuticals Inc. is a private company focused on the development of oncology therapeutics and companion diagnostics.
An unfortunate side effect of the platinum-chemotherapy drug oxaliplatin is the development of neurotoxicity, which can adversely affect a patient's quality of life; therefore, the benefit of oxaliplatin-based therapy must be balanced with prevention of neuropathies. Currently, there are no therapeutic interventions available to relieve oxaliplatin-associated neurological symptoms, which are thought to be a result of reactive oxygen species-associated damage.
› Verified 6 days ago
Nicole L Cross-hillman, PSY.D. Psychologist Medicare: Medicare Enrolled Practice Location: 1800 E Interstate Ave Ste B, Bismarck, ND 58503 Phone: 701-323-6543 Fax: 701-323-5492 | |
Dr. Craig Degree, PHD Psychologist Medicare: Not Enrolled in Medicare Practice Location: 900 E Broadway Ave, Bismarck, ND 58501 Phone: 701-530-7300 Fax: 701-530-7319 | |
Christine Jean Kuchler, PHD Psychologist Medicare: Not Enrolled in Medicare Practice Location: 1237 W Divide Ave, Ste 5, Bismarck, ND 58501 Phone: 701-328-8877 Fax: 701-328-8900 | |
Richard E Arndorfer, PHD Psychologist Medicare: Accepting Medicare Assignments Practice Location: 1800 E Interstate Ave Ste B, Bismarck, ND 58503 Phone: 701-323-6543 | |
Mrs. Rebecca Ann Woolsey, APRN Psychologist Medicare: Accepting Medicare Assignments Practice Location: 900 E Broadway Ave, Bismarck, ND 58501 Phone: 701-530-7000 | |
Dr. Kathy Blohm, PHD Psychologist Medicare: Accepting Medicare Assignments Practice Location: 1701 Burnt Boat Dr, Second Floor, Bismarck, ND 58503 Phone: 701-323-0924 Fax: 701-323-0935 | |
Dr. Nova Marie Griffith, PH.D. Psychologist Medicare: Medicare Enrolled Practice Location: 515 1/2 E Broadway Ave, Suite 106, Bismarck, ND 58501 Phone: 701-751-0443 Fax: 701-751-1616 |